⁶⁸Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia

CONTEXT: Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. OBJECTIVE: Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). DESIGN: This was a single-center prospective study of patients with TIO. SETTING: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. SUBJECTS: Eleven subjects (six females, five males) with TIO were included. INTERVENTION: F FDG-PET/CT) scan. MAIN OUTCOME MEASURES: Localization of PMTs on the previously described imaging modalities were determined. RESULTS: Ga-DOTATATE the only imaging study to identify the tumor. CONCLUSIONS: Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.